Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $190M | $28M | $21M | $47M | 4.6% | - | -111.9% |
| 2024 | $0M | $-174M | $-176M | $-69M | -71.7% | - | 351.0% |
| 2023 | $0M | $-37M | $-39M | $-25M | -24.8% | - | 62.0% |
| 2022 | $0M | $-22M | $-24M | $-21M | -232.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 190.40 |
| Operating Revenue | 190.40 |
| Cost Of Revenue | 2.70 |
| Gross Profit | 187.70 |
| Operating Expense | 172.76 |
| Research And Development | 40.63 |
| Selling General And Administration | 132.13 |
| Total Expenses | 175.46 |
| Operating Income | 14.95 |
| Total Operating Income As Reported | 9.41 |
| EBITDA | 28.38 |
| Normalized EBITDA | 33.92 |
| EBIT | 26.37 |
| Interest Income | 16.95 |
| Interest Expense | 5.48 |
| Net Interest Income | 11.48 |
| Other Income Expense | -5.54 |
| Interest Income Non Operating | 16.95 |
| Interest Expense Non Operating | 5.48 |
| Net Non Operating Interest Income Expense | 11.48 |
| Pretax Income | 20.89 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 20.89 |
| Net Income From Continuing And Discontinued Operation | 20.89 |
| Net Income From Continuing Operation Net Minority Interest | 20.89 |
| Net Income | 20.89 |
| Net Income Common Stockholders | 20.48 |
| Net Income Including Noncontrolling Interests | 20.89 |
| Normalized Income | 26.43 |
| Diluted NI Availto Com Stockholders | 20.48 |
| Basic Average Shares | 50.82 |
| Diluted Average Shares | 52.38 |
| Reconciled Depreciation | 2.02 |
| Reconciled Cost Of Revenue | 2.70 |
| Total Unusual Items | -5.54 |
| Total Unusual Items Excluding Goodwill | -5.54 |
| Special Income Charges | -5.54 |
| Restructuring And Mergern Acquisition | 5.54 |
| Gain On Sale Of Security | - |
| General And Administrative Expense | - |
| Other Gand A | - |
| Otherunder Preferred Stock Dividend | 0.42 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Soleno Therapeutics, Inc.this co. | SLNO | $2.8B | 132.26 | 6.14 | 4.6% | 96.72 |
| LifeStance Health Group, Inc. | LFST | $2.9B | 301.90 | 1.92 | 0.6% | 39.90 |
| Adaptive Biotechnologies Corporation | ADPT | $2.9B | - | 13.23 | -27.2% | - |
| GRAIL, Inc. | GRAL | $2.9B | -6.99 | 1.11 | -15.8% | -7.04 |
| Brookdale Senior Living Inc. | BKD |
| - |
| - |
| - |
| - |
| $2.8B |
| -10.81 |
| -63.45 |
| 587.0% |
| 23.48 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.7B | -170.10 | 14.49 | -8.5% | 1582.53 |
| Disc Medicine, Inc. | IRON | $2.7B | -12.80 | 3.67 | -28.7% | -12.77 |
| Definium Therapeutics, Inc. | DFTX | $2.7B | -14.59 | 8.07 | -55.3% | -13.82 |
| Alumis Inc. | ALMS | $2.6B | -10.68 | 8.63 | -80.8% | -5.66 |
| Peer Median | - | -10.81 | 5.87 | -21.5% | -5.66 | |